COMPANY PROFILE

Beyang Therapeutics

Request full access

AI-driven ExCEED platform for novel drug discovery and optimization

Huangpu, ChinaFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Beyang Therapeutics

Beyang Therapeutics (成都必扬医药科技有限公司 / 必扬医药; formerly branded Txbeyond / Beyond Therapeutics) is an innovative biopharmaceutical company founded in 2021 that uses its proprietary ExCEED AI-driven molecular design and optimization platforms to accelerate new drug discovery for disease areas with significant unmet medical need. Pipeline programs include BT01001, a small-molecule eye drop for severe non-proliferative diabetic retinopathy that has completed Phase I SAD/MAD studies, and BY002/BT01002, a second-generation Menin inhibitor for AML/ALL with KMT2A-r or NPM1 mutations. The company closed an oversubscribed nearly RMB200M / ~US$30M Series A in mid-2026, co-led by Legend Capital and Shanghai Healthcare Capital / Shanghai Biomedical Innovation and Transformation Fund.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Huangpu, China
Employees: 4
Open positions: None listed
Dealroom signal: 57.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: B2B
Links: Website LinkedIn

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom

Market maps in Biotech & Life Sciences

Market map Rare Disease Therapeutics & Technologies Landscape

Market map Digital therapeutics

Market map Psychedelic therapeutics

Open roles

Track hiring at Beyang TherapeuticsOpen roles, team growth and hiring by functionBook a demo

Looking for a job? The startup jobs board lists open roles.Startups hiring now →

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Aug 2026	$30M	$120M	Shanghai Healthcare Capital · Legend Capital	↗
SEED✓Equity / VC	Jul 2023	$2.8M	$11M	Suzhou Sansu New Drug Development · Ming Bioventures · Shanghai Intertek Industrial	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Beyang Therapeutics website traffic

Latest recorded traffic for Beyang Therapeutics is 30 monthly website visits, down 87% over the last three months. Beyang Therapeutics's team grew 0% over the past year.

Latest monthly visits30 3-month web change-87% 1-year team growth0%

Monthly website visitsJul 2023–Jun 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SMSuperluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created	Boston, United States	Operational	60	$213M	$240M
MEMetapinesNovel pharmaceutical composition for cancer treatment, where different compounds are simultaneously uptaken into cancer cells	Seongnam-si, South Korea	Operational
RMRVAC MedicinesMRNA platform company engaged in the research and development of innovative products such as vaccines for diseases	Singapore	Operational
APArthur PharmaHigh-tech innovative pharmaceutical manufacturer	Jiaxing, China	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational
CUCurifyLabsEnables sustainable, on-demand manufacture of medicines customized to provide safe and effective treatment for all patients	Helsinki, Finland	Operational
SESentanteDeveloping a radiation-reducing manipulator and a minimally invasive coronary robotic system for endovascular procedures	Kaunas, Lithuania	Operational